Covid-19: What now for remdesivir?
Author:
Publisher
BMJ
Subject
General Engineering
Reference31 articles.
1. WHO downgrades status of oseltamivir
2. The Tamiflu fiasco and lessons learnt
3. Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19
4. Pardo J, Shukla AM, Chamarthi G, Gupte A. The journey of remdesivir: from Ebola to covid-19. Drugs Context. 2020;9:2020-4-14.
5. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe covid-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020 16;395(10236):1569-78.
Cited by 38 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Remdesivir-Related Cardiac Adverse Effects in COVID-19 Patients: A Case-Control Study;Drug Research;2024-07
2. Uncovering the Power of GPR18 Signalling: How RvD2 and Other Ligands Could Have the Potential to Modulate and Resolve Inflammation in Various Health Disorders;Molecules;2024-03-12
3. Low-Data Drug Design with Few-Shot Generative Domain Adaptation;Bioengineering;2023-09-21
4. Bench-to-bedside: Innovation of small molecule anti-SARS-CoV-2 drugs in China;European Journal of Medicinal Chemistry;2023-09
5. Aprotinin—Drug against Respiratory Diseases;International Journal of Molecular Sciences;2023-07-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3